Breast cancer susceptibility testing: past, present and future

References

• Lacroix M, Leclercq G. The “portrait” of hereditary breast cancer. Breast Cancer Res. Treat.89(3), 297–304 (2005).
   PubMed Web of Science ®Google Scholar
• Chen S, Iversen ES, Friebel T et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J. Clin. Oncol.24(6), 863–871 (2006).
   PubMed Web of Science ®Google Scholar
• de Jong MM, Nolte IM, te Meerman GJ et al. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J. Med. Genet.39(4), 225–242 (2002).
   PubMed Web of Science ®Google Scholar
• Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science250(4985), 1233–1238 (1990).
   PubMed Web of Science ®Google Scholar
• Waite KA, Eng C. Protean PTEN: form and function. Am. J. Hum. Genet.70(4), 829–844 (2002).
   PubMed Web of Science ®Google Scholar
• Hall JM, Lee MK, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science250(4988), 1684–1689 (1990).
   PubMed Web of Science ®Google Scholar
• Couch FJ, Kiousis S, Castilla LH et al. Characterization of 10 new polymorphic dinucleotide repeats and generation of a high-density microsatellite-based physical map of the BRCA1 region of chromosome 17q21. Genomics24(3), 419–424 (1994).
   PubMed Web of Science ®Google Scholar
• Cropp CS, Champeme MH, Lidereau R, Callahan R. Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequently deleted. Cancer Res.53(23), 5617–5619 (1993).
   PubMed Web of Science ®Google Scholar
• Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science266(5182), 66–71 (1994).
   PubMed Web of Science ®Google Scholar
• Futreal PA, Liu Q, Shattuck-Eidens D et al.BRCA1 mutations in primary breast and ovarian carcinomas. Science266(5182), 120–122 (1994).
   PubMed Web of Science ®Google Scholar
• Wooster R, Neuhausen SL, Mangion J et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science265(5181), 2088–2090 (1994).
   PubMed Web of Science ®Google Scholar
• Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature378(6559), 789–792 (1995).
   PubMed Web of Science ®Google Scholar
• Tavtigian SV, Simard J, Rommens J et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat. Genet.12(3), 333–337 (1996).
   PubMed Web of Science ®Google Scholar
• Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA68(4), 820–823 (1971).
   PubMed Web of Science ®Google Scholar
• Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12–21 in familial breast and ovarian cancer involve the wildtype chromosome. Nat. Genet.2(2), 128–131 (1992).
   PubMed Web of Science ®Google Scholar
• Collins N, McManus R, Wooster R et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12–13. Oncogene10(8), 1673–1675 (1995).
   PubMed Web of Science ®Google Scholar
• Shattuck-EidensD, Oliphant A, McClure M et al.BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA278(15), 1242–1250 (1997).
   PubMed Web of Science ®Google Scholar
• Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell108(2), 171–182 (2002).
   PubMed Web of Science ®Google Scholar
• Welcsh PL, Lee MK, Gonzalez-Hernandez RM et al. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc. Natl Acad. Sci. USA99(11), 7560–7565 (2002).
   PubMed Web of Science ®Google Scholar
• Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer4(9), 665–676 (2004).
   PubMed Web of Science ®Google Scholar
• Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet.10(7), 705–713 (2001).
   PubMed Web of Science ®Google Scholar
• Liu Y, West SC. Distinct functions of BRCA1 and BRCA2 in double-strand break repair. Breast Cancer Res.4(1), 9–13 (2002).
   PubMed Web of Science ®Google Scholar
• Yang H, Jeffrey PD, Miller J et al.BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science297(5588), 1837–1848 (2002).
   PubMed Web of Science ®Google Scholar
• Honrado E, Benitez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod. Pathol.18(10), 1305–1320 (2005).
   PubMed Web of Science ®Google Scholar
• Hogervorst FB, Cornelis RS, Bout M et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat. Genet.10(2), 208–212 (1995).
   PubMed Web of Science ®Google Scholar
• Andrulis IL, Anton-Culver H, Beck J et al. Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum. Mutat.20(1), 65–73 (2002).
   PubMed Web of Science ®Google Scholar
• Simard J, Tonin P, Durocher F et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat. Genet.8(4), 392–398 (1994).
   PubMed Web of Science ®Google Scholar
• Gorski B, Jakubowska A, Huzarski T et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int. J. Cancer110(5), 683–686 (2004).
   PubMed Web of Science ®Google Scholar
• Tulinius H, Olafsdottir GH, Sigvaldason H et al. The effect of a single BRCA2 mutation on cancer in Iceland. J. Med. Genet.39(7), 457–462 (2002).
   PubMed Web of Science ®Google Scholar
• de Bock GH, Tollenaar RA, Papelard H et al. Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients. Br. J. Cancer85(9), 1347–1350 (2001).
   PubMed Web of Science ®Google Scholar
• Einbeigi Z, Bergman A, Kindblom LG et al. A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer. Eur. J. Cancer37(15), 1904–1909 (2001).
   PubMed Web of Science ®Google Scholar
• Heimdal K, Maehle L, Apold J, Pedersen JC, Moller P. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. Eur. J. Cancer39(15), 2205–2213 (2003).
   PubMed Web of Science ®Google Scholar
• Satagopan JM, Offit K, Foulkes W et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol. Biomarkers Prev.10(5), 467–473 (2001).
   PubMed Web of Science ®Google Scholar
• Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med.336(20), 1401–1408 (1997).
   PubMed Web of Science ®Google Scholar
• Struewing JP, Abeliovich D, Peretz T et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat. Genet.11(2), 198–200 (1995).
   PubMed Web of Science ®Google Scholar
• Oddoux C, Struewing JP, Clayton CM et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat. Genet.14(2), 188–190 (1996).
   PubMed Web of Science ®Google Scholar
• Newman B, Mu H, Butler LM et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA279(12), 915–921 (1998).
   PubMed Web of Science ®Google Scholar
• Kim SW, Lee CS, Fey JV, Borgen PI, Boyd J. Prevalence of BRCA2 mutations in a hospital based series of unselected breast cancer cases. J. Med. Genet.42(1), E5 (2005).
   Google Scholar
• King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science302(5645), 643–646 (2003).
   PubMed Web of Science ®Google Scholar
• Antoniou AC, Pharoah PD, Narod S et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J. Med. Genet.42(7), 602–603 (2005).
   PubMed Web of Science ®Google Scholar
• Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet.72(5), 1117–1130 (2003).
   PubMed Web of Science ®Google Scholar
• Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet.62(3), 676–689 (1998).
   PubMed Web of Science ®Google Scholar
• Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am. J. Hum. Genet.68(2), 410–419 (2001).
   PubMed Web of Science ®Google Scholar
• Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol. Biomarkers Prev.14(1), 20–26 (2005).
   PubMed Web of Science ®Google Scholar
• Chappuis PO, Nethercot V, Foulkes WD. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin. Surg. Oncol.18(4), 287–295 (2000).
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Metcalfe K, Hanna W et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer98(8), 1569–1577 (2003).
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst.95(19), 1482–1485 (2003).
   PubMed Web of Science ®Google Scholar
• Arnes JB, Brunet JS, Stefansson I et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin. Cancer Res.11(11), 4003–4011 (2005).
   PubMed Web of Science ®Google Scholar
• Rubin SC. BRCA-related ovarian carcinoma. Cancer97(9), 2127–2129 (2003).
   PubMed Web of Science ®Google Scholar
• Frank TS, Deffenbaugh AM, Reid JE et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J. Clin. Oncol.20(6), 1480–1490 (2002).
   PubMed Web of Science ®Google Scholar
• Hampel H, Sweet K, Westman JA, Offit K, Eng C. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J. Med. Genet.41(2), 81–91 (2004).
   PubMed Web of Science ®Google Scholar
• Claus EB. Risk models used to counsel women for breast and ovarian cancer: a guide for clinicians. Fam. Cancer1(3–4), 197–206 (2001).
   PubMedGoogle Scholar
• Green MJ, Botkin JR. “Genetic exceptionalism” in medicine: clarifying the differences between genetic and nongenetic tests. Ann. Int. Med.138(7), 571–575 (2003).
   PubMed Web of Science ®Google Scholar
• Walsh T, Casadei S, Coats KH et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA295(12), 1379–1388 (2006).
   PubMed Web of Science ®Google Scholar
• Ponder B. Genetic testing for cancer risk. Science278(5340), 1050–1054 (1997).
   PubMed Web of Science ®Google Scholar
• Cullinane CA, Lubinski J, Neuhausen SL et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int. J. Cancer117(6), 988–991 (2005).
   PubMed Web of Science ®Google Scholar
• Jernstrom H, Lubinski J, Lynch HT et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J. Natl Cancer Inst.96(14), 1094–1098 (2004).
   PubMed Web of Science ®Google Scholar
• Milne RL, Knight JA, John EM et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol. Biomarkers Prev.14(2), 350–356 (2005).
   PubMed Web of Science ®Google Scholar
• Ghadirian P, Lubinski J, Lynch H et al. Smoking and the risk of breast cancer among carriers of BRCA mutations. Int. J. Cancer110(3), 413–416 (2004).
   PubMed Web of Science ®Google Scholar
• Nkondjock A, Ghadirian P, Kotsopoulos J et al. Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int. J. Cancer118(1), 103–107 (2006).
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J. Clin. Oncol.22(6), 1055–1062 (2004).
   PubMed Web of Science ®Google Scholar
• Meijers-Heijboer H, van Geel B, van Putten WL et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med.345(3), 159–164 (2001).
   PubMed Web of Science ®Google Scholar
• Garcia-Etienne CA, Borgen PI. Update on the indications for nipple-sparing mastectomy. J. Support Oncol.4, 225–230 (2006).
   PubMedGoogle Scholar
• Hartmann LC, Sellers TA, Schaid DJ et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J. Natl Cancer Inst.93(21), 1633–1637 (2001).
   PubMed Web of Science ®Google Scholar
• Kauff ND, Satagopan JM, Robson ME et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med.346(21), 1609–1615 (2002).
   PubMed Web of Science ®Google Scholar
• Eisen A, Lubinski J, Klijn J et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J. Clin. Oncol.23(30), 7491–7496 (2005).
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst.97(22), 1652–1662 (2005).
   PubMed Web of Science ®Google Scholar
• King MC, Wieand S, Hale K et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA286(18), 2251–2256 (2001).
   PubMed Web of Science ®Google Scholar
• Brekelmans CT, Seynaeve C, Bartels CC et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J. Clin. Oncol.19(4), 924–930 (2001).
   PubMed Web of Science ®Google Scholar
• Carney PA, Miglioretti DL, Yankaskas BC et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann. Int. Med.138(3), 168–175 (2003).
   PubMed Web of Science ®Google Scholar
• Warner E, Plewes DB, Hill KA et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA292(11), 1317–1325 (2004).
   PubMed Web of Science ®Google Scholar
• Robson ME, Offit K. Breast MRI for women with hereditary cancer risk. JAMA292(11), 1368–1370 (2004).
   PubMed Web of Science ®Google Scholar
• Newman LA, Kuerer HM. Advances in breast conservation therapy. J. Clin. Oncol.23(8), 1685–1697 (2005).
   PubMed Web of Science ®Google Scholar
• Haffty BG, Harrold E, Khan AJ et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet359(9316), 1471–1477 (2002).
   PubMed Web of Science ®Google Scholar
• Vinh-Hung V, Verschraegen C. Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J. Natl Cancer Inst.96(2), 115–121 (2004).
   PubMed Web of Science ®Google Scholar
• Pierce LJ, Levin AM, Rebbeck TR et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J. Clin. Oncol.24(16), 2437–2443 (2006).
   PubMed Web of Science ®Google Scholar